Best Oncology Companies in Texas, United States
The 160 best Oncology companies in Texas, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Caris Life Sciences.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Texas
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Caris Life Sciences 🦄 Developer of panomic disease profiling technologies for cancer precision medicine 78Moat top 15%Funding top 17%Product top 19%Market top 28% All 9 signals ▾Moattop 15% Fundingtop 17% Producttop 19% Markettop 28% Innovationtop 38% Growthtop 40% Newstop 43% Techtop 44% Globaltop 46% Moat: Editorial + unicorn rating 9/10 · Unicorn Funding: Raised $1.1B across 6 rounds · 6 rounds over 9 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 78/100 | $1.1B | 14 mo ago | 1,339 | — | WordPress Site EditorCart FunctionalityWordPress+19 | — | — |
| 2 | Peloton Therapeutics Developer of small molecule therapeutics to treat kidney cancer | $243M | 87 mo ago | 62 | Steven McKnight Co-Founder | — | 150 patents Develops small-molecule oncology drugs targeting HIF-2α, Hippo pathway, and novel scaffolds. | — |
| 3 | Marker Therapeutics Developer of T-cell based therapeutics for cancer treatment 42Talent top 15%Funding top 18%News top 47%Tech top 50% All 9 signals ▾Talenttop 15% Fundingtop 18% Newstop 47% Techtop 50% Moattop 50% Marketbottom 43% Growthbottom 40% Globalbottom 32% Fin. healthbottom 29% Talent: Analyst team rating 5/5 Funding: Raised $154M across 23 rounds · 23 rounds over 10 yrs (2.3/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $154M | 9 mo ago | 67 | — | DrupalApple iCloud MailMicrosoft 365+22 | — | — |
| 4 | Bellicum Developer of T cell therapies for the treatment of cancer and chronic infectious diseases | $138M | 141 mo ago | 108 | — | DrupalApple iCloud MailMicrosoft 365+20 | — | — |
| 5 | CoRegen Developer of a novel cancer therapy targeting Treg cells | $121M | 11 mo ago | — | John Thomas CFO | — | — | — |
| 6 | Aspira Women's Health Provider of diagnostic solution for ovarian malignancy in women 32Funding top 29%Tech top 46%Market bottom 46%Fin. health bottom 36% All 7 signals ▾Fundingtop 29% Techtop 46% Marketbottom 46% Fin. healthbottom 36% Growthbottom 35% Globalbottom 30% Newsbottom 21% Funding: Raised $96.7M across 8 rounds · 8 rounds over 16 yrs (0.5/yr) Tech: 36 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 32/100 | $97M | 9 mo ago | 85 85 → 60 (-29%) | — | WordPressApple iCloud MailMySQL+25 | — | 2 partnerships |
| 7 | Tvardi Developer of small molecule based therapeutics for cancer treatment | $83M | 60 mo ago | 15 | — | WordPressDrupalMySQL+24 | — | — |
| 8 | Asuragen Molecular diagnostics and genetics company advancing precision medicine in oncology | $80M | 80 mo ago | 114 114 → 101 (-11%) | — | WordPressApple iCloud MailMicrosoft 365+19 | 351 patents Detecting and analyzing repeat-rich nucleic acids and miRNA biomarkers for diagnostics. | 1 partnership |
| 9 | Mirna Therapeutics Developing microRNA-based oncology therapies for solid and hematologic cancers | $78M | 133 mo ago | 27 | Jose Carlos Gutierrez Ramos CEO & President | — | — | — |
| 10 | Mirna Therapeutics Developing microRNA-based therapeutics for cancer treatment. | $78M | 133 mo ago | 72 | — | — | — | — |
| 11 | Actuate Therapeutics Developer of therapeutics for hard-to-treat cancer | $72M | 11 mo ago | 6 | Dan Schmitt President and CEO | WordPressMySQLPHP+16 | — | 1 launch |
| 12 | OncoNano Developer of a compound that exploits pH as a biomarker to diagnose and treat cancer | $68M | 14 mo ago | 20 20 → 22 (+10%) | Marty Driscoll CEO | Cart FunctionalitySquarespace CommerceSquarespace+16 | — | — |
| 13 | Gradalis Personalized cancer immunotherapy company advancing treatment through Vigil platform | $68M | 12 mo ago | 8 | — | — | 179 patents Nucleic‑acid therapeutics targeting cancer and genetic muscle disorders, including RNAi and neoantigen vaccines. | — |
| 14 | Allterum Developer of drugs for treating leukemia disease | $66M | 52 mo ago | 2 | — | — | — | — |
| 15 | Castle Biosciences Provider of diagnostic devices for treating cancer | $62M | 82 mo ago | 324 324 → 751 (+132%) | Derek Maetzold President | WebflowCart FunctionalitySalesforce+24 | 82 patents Molecular diagnostics and prognostics for skin cancers and inflammatory skin diseases. | 1 award |
| 16 | Protom International Proton radiotherapy system | $62M | 111 mo ago | 40 | — | GoDaddy Website BuilderReactRequireJS+7 | — | — |
| 17 | Triumvira Immunologics Developer of T-cell therapies for treating cancers | $55M | 51 mo ago | 85 | Jonathan Bramson Co-Founder & Chairman | — | 48 patents Bispecific T‑cell engager antibodies targeting Claudin‑18.2, GUCY2C, and GPC3 for cancer immunotherapy. | — |
| 18 | Medicenna Therapeutics Developer of interleukin-4 Receptor (IL4R) targeted cytokines for cancer | $54M | 25 mo ago | 1 | — | DrupalPHPBootstrap+22 | — | — |
| 19 | ImmunoGenesis Developer of therapeutic solutions for treating tumors | $44M | 27 mo ago | 14 | Michael Curran Founder | WordPressMySQLPHP+18 | 18 patents Targeted hypoxia‑activated prodrugs and STING agonist combos for cancer immunotherapy | — |
| 20 | DNAtrix Oncolytic virus platform for treating malignant glioma. | $43M | 45 mo ago | 13 | — | — | 81 patents Oncolytic adenovirus gene therapies targeting pediatric brain tumors and immune activation | — |
| 21 | RadioMedix Developer of targeted radiopharmaceuticals for cancer diagnosis and treatment | $40M | 44 mo ago | 26 | Izabela Tworowska Co-Founder & CSO | WordPressMySQLPHP+14 | 65 patents Automated production of lead‑212 radionuclide for targeted alpha‑particle cancer therapy | — |
| 22 | Sporos Bioventures Developer of therapies for cancer and immune diseases | $38M | 61 mo ago | — | Peter Feinberg Co-Founder | — | — | — |
| 23 | March Biosciences Developer of CAR-T cell therapies for malignancies | $33M | 20 mo ago | — | Max Mamonkin Co-Founder and CSO | — | — | — |
| 24 | CoRegen Developer of immunotherapeutics for the treatment of cancer | $27M | 13 mo ago | — | Steve Gorlin CEO | — | — | — |
| 25 | Iterion Therapeutics Developer of therapeutics for the treatment of cancer | $25M | 64 mo ago | 10 | Rahul Aras CEO & President | WordPress Block EditorWordPressMySQL+17 | — | — |
| 26 | Nanospectra Developer of nanoparticle-based cancer treatment for solid tumors | $25M | 39 mo ago | 9 | — | WordPressMySQLPHP+17 | — | — |
| 27 | Emtora Biosciences Developer of reformulating for treating cancers and other age-related disorders | $24M | 46 mo ago | 3 | — | — | — | — |
| 28 | PLUS THERAPEUTICS Provider of therapeutics for multiple cancer treatments | $24M | 16 mo ago | 20 20 → 27 (+35%) | Marc Hedrick CEO | WordPressBugHerdApple iCloud Mail+39 | — | 1 partnership |
| 29 | CNS Pharmaceuticals Developer of treatments for primary and metastatic cancers in the brain and central nervous system 42Funding top 23%News top 23%Growth top 25%Talent top 43% All 7 signals ▾Fundingtop 23% Newstop 23% Growthtop 25% Talenttop 43% Techbottom 45% Globalbottom 43% Marketbottom 19% Funding: Raised $22.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) News: 6 BI events in 12 mo (of 33 tracked, 7 types) · +200% YoY rank vs industry peers · Fliar Intelligence Index 42/100 | $23M | 1 mo ago | 5 | John Climaco CEO | WordPressMySQLPHP+15 | — | 1 job opening |
| 30 | Invectys Developer of immunotherapeutic cancer treatments targeting HLA‑G antigen | $22M | 20 mo ago | 25 | Simon Wain-Hobson Co-Founder & CSO | WordPressMySQLPHP+19 | 4 patents Engineered CAR‑T cell immunotherapy targeting HLA‑G antigen | — |
| 31 | Coya Therapeutics Developer of therapeutics for cell therapy and exosome therapy | $20M | 19 mo ago | 6 | — | WordPressMySQLPHP+14 | — | — |
| 32 | Orano Med Developing targeted cancer therapies using Lead-212 radioisotope for alphatherapy | $15M | 29 mo ago | — | Julien Dodet President and CEO | Progress SitefinitySalesforcePIXIjs+20 | — | — |
| 33 | 7 Hills Pharma Developing integrin agonists to improve immunotherapies for cancer and genetic diseases | $15M | 25 mo ago | 9 | Upendra Marathi President & CEO | Cart FunctionalitySquarespace CommerceSquarespace+13 | — | — |
| 34 | Asylia Therapeutics Developer of medicines for cancer, autoimmune, and infectious diseases | $14M | 14 mo ago | 4 | Richard Jones Co-Founder | — | — | — |
| 35 | Memgen Developer of immunotherapies to treat cancer | $12M | 18 mo ago | 9 | — | — | 72 patents Oncolytic virus and CD40/TLR‑based immunotherapy platforms for cancer and vaccines | — |
| 36 | Tachyon Developer of therapeutics for cancer | $12M | 39 mo ago | 5 | Frank Perabo CEO | — | 8 patents Wireless multiple-access protocols, time synchronization, and spectrum allocation for CDMA systems | — |
| 37 | Diakonos Provider of immunotherapeutics for cancer treatment | $11M | 12 mo ago | — | Mike Wicks CEO | WordPressMySQLPHP+18 | — | 1 partnership |
| 38 | Bio Developer of therapeutics for the treatment of cancer | $10M | 24 mo ago | 10 | — | — | — | — |
| 39 | ImmunoMet Therapeutics Biotech targeting cellular metabolism for novel anti-cancer and anti-fibrosis therapies | $10M | 4 mo ago | 9 | Dean Welsch CEO | — | — | — |
| 40 | CrossBridge Bio Developer of Antibody-Drug Conjugate therapeutics | $10M | 19 mo ago | — | Zhiqiang An Co-Founder | WordPressMySQLPHP+19 | — | — |
| 41 | Moleculin Biotech Small molecule drugs for leukemia and other cancers | $10M | 3 mo ago | 19 19 → 22 (+16%) | — | WordPressMySQLPHP+22 | 37 patents Liposomal formulation and lyophilized delivery of annamycin anticancer agent. | — |
| 42 | Stingray Therapeutics Developer of immunotherapeutics for treating cancer | $8M | 15 mo ago | 6 | Sunil Sharma Co-Founder | — | — | — |
| 43 | C4 Imaging Provider of Image-guided procedures for the treatment of prostate cancer | $7M | 28 mo ago | 4 | — | — | — | — |
| 44 | Prana Thoracic Developer of minimally invasive lung tissue excision tool for lung cancer | $6M | 24 mo ago | 9 | Joanna Nathan Founder & CEO | — | 27 patents Advanced control and sealing systems for minimally invasive thoracic tissue resection. | — |
| 45 | Greenwich LifeSciences Developer of peptide-based immunotherapy for cancer treatment | $2M | 24 mo ago | 3 | Eric Rothe Founder | WordPressMySQLPHP+26 | 7 patents Immunomodulatory therapies and predictive immune biomarkers for cancer survival improvement | — |
| 46 | Hera Biotech Developer of diagnostic test kit for endometriosis | $2M | 9 mo ago | 5 | Bruce Nicholson Co-Founder | JoomlaPHPCentOS+13 | — | — |
| 47 | Prana Thoracic Developer of solutions for early intervention in lung cancer | $2M | 14 mo ago | — | Richard Fischel Co-Founder | WebflowjQueryHSTS+9 | 27 patents Patents concentrated in health & consumer products | — |
| 48 | Affirmed Pharma Translational drug development company specializing in late-stage therapeutics | $1M | 15 mo ago | — | John Weatherspoon Co-Founder | — | — | — |
| 49 | Alaunos Therapeutics Developer of adoptive TCR-T cell therapies for solid tumors. | $850K | 11 mo ago | 34 | — | DrupalPHPAmazon Web Services+20 | — | — |
| 50 | ReEngage Developer of therapeutics for longevity-related diseases | $365K | 12 mo ago | — | Gottlieb Co-Founder | — | — | 1 partnership |
Top 12 Oncology companies in Texas
#1
Public · Irving, Texas · founded 1996 · 1339 employees$1.1Braised▾
Developer of panomic disease profiling technologies for cancer precision medicine. The company leverages artificial intelligence (AI) and machine learning algorithms. Leveraging our proprietary AI analytics engine, DEAN for advancing the oncology precision medicine platform. It offers tumor profiling services, a complete molecular blueprint, and guiding personalized cancer treatment.
- Apr 2025Series D$168M
- Jan 2023Conventional Debt—
- May 2021Series D$830M
- Oct 2020Conventional Debt$75M
#2
Public · Houston, Texas · founded 2017 · 5 employees$22.5Mraised▾
Developer of treatments for primary and metastatic cancers in the brain and central nervous system. It offers a pipeline of anti-cancer drug candidates including berubicin that appears to cross the blood brain barrier and kill tumor cells and TPI 287 for glioblastoma multiforme.
- May 2026Series B$22.5M
#3
Public · Houston, Texas · founded 1991 · 67 employees$153.9Mraised▾
Developer of T-cell based therapeutics for cancer treatment. The company's lead product candidates are used against triple-negative breast cancer and ovarian cancer. The company is also developing peptide vaccines for the treatment purpose.
- Aug 2025Grant (prize money)$1.3M
- Jun 2025Grant (prize money)$1.2M
- May 2025Grant (prize money)$2M
- Apr 2025Grant (prize money)$2M
#4
Public · Austin, Texas · founded 1993 · 85 employees$96.7Mraised▾
Provider of diagnostic solution for ovarian malignancy in women. It offers products OVA1 and OVERA to detect the risk of ovarian cancer for patients. It also offers its flagship product for the detection of risk heredity breast and ovary cancer; ASPiRA GenetiXSM testing which offers comprehensive genetic testing options with a gynecologic focus.
- Sep 2025Post IPO$3M
- Mar 2025Post IPO$1.4M
- Jun 2024Post IPO$1.9M
- Jul 2020Post IPO$11M
#5
Public · Houston, Texas · founded 2006 · 19 employees$9.7Mraised▾
Moleculin Biotech is preclinical and clinical-stage company focused on the development of anti-cancer drug candidates and was founded based on the discoveries made at M.D. Anderson Cancer Center. Its lead product candidate Annamycin, an anthracycline molecule will be entering phase IIb trials for the treatment of relapsed or refractory acute myeloid leukemia. Its small molecules pipeline also has WP1066 portfolio 3 candidates which are focused on the modulation of tumor cell signaling mechanisms WP1122 that targets the metabolism of tumors. These candidates are in the IND-filing phase for Cutaneous T-cell lymphoma, Glioblastoma, and Pancreatic cancer.
- Feb 2026Post IPO$8.3M
- Feb 2018Post IPO$9M
- Dec 2017Grant (prize money)$2M
- Oct 2014Conventional Debt$1.4M
#6
Series C · Houston, Texas · founded 2003$121.4Mraised▾
Developer of a novel cancer therapy targeting Treg cells. This therapy aims to eradicate cancer by modifying a single gene in regulatory T cells (Tregs), thereby enabling the immune system to recognize and destroy cancer cells without causing toxicity or inflammation. Pre-clinical trials have shown promising results, and the company is progressing towards human clinical trials. The therapy is designed for outpatient administration, simplifying the treatment process for patients. The technology is based on decades of research in steroid receptor coactivators and is protected by patents.
- Jul 2025Series C$93.4M
- 2024Series B$28M
#7
Public · Fort Worth, Texas · founded 2015 · 6 employees$72.2Mraised▾
Developer of therapeutics for hard-to-treat cancer. It offers a lead drug candidate elraglusib a GSK-3β inhibitor that also modulates antitumor immunity to slow tumor growth and counteract resistance. It is used for the treatment of melanoma, pediatric cancer, pancreatic cancer, and others.
- Jun 2025Post IPO$4.7M
- Feb 2024Series D$3M
- Dec 2022Series D$19.3M
- Dec 2020Series C$14.5M
#8
Series B · Houston, Texas · founded 2015 · 9 employees$10.2Mraised▾
Biotech targeting cellular metabolism for novel anti-cancer and anti-fibrosis therapies. The company focuses on developing innovative treatments by leveraging the unique metabolic signatures of cancer and immune cells. Their lead molecule targets Oxidative Phosphorylation, aiming to decrease aberrant cell growth and proliferation in targeted cancer cells and fibrosis. They are developing a library of biguanides with the potential for development as novel treatments for cancer and/or diseases of fibrosis. The company is dedicated to advancing science and improving patient outcomes through targeted therapeutic interventions in oncology and fibrosis. They are a clinical stage company.
- Jan 2026Series B$842.2K
- Mar 2017Series B$5M
- Mar 2016Series A$5.2M
#9
Series C · Carrollton, Texas · founded 2010 · 8 employees$67.9Mraised▾
Personalized cancer immunotherapy company advancing treatment through Vigil platform. This biotechnology company focuses on developing personalized therapeutics to treat cancer. They are developing Vigil, a proprietary immunotherapy platform for multiple advanced cancer indications. Vigil empowers a patient’s own immune system to identify and destroy cancer cells. Vigil's patient-specific approach has demonstrated success in research and clinical trial phases in treating ovarian cancer, with potential applications across other solid tumor types. Vigil can be used alone or in concert with other treatments. They are advancing cancer treatment through personalized immunotherapy. The company is focused on scientific research, medical research, and technology to make a difference in cancer treatment.
- Jun 2025Series C$12.7M
- Nov 2023Grant (prize money)$9.9M
- Mar 2018Series C$43.9M
- Jan 2013Series B$24M
#10
Series B · Southlake, Texas · founded 2014 · 20 employees$68.4Mraised▾
Developer of a compound that exploits pH as a biomarker to diagnose and treat cancer. The product candidates are designed to help patients across cancer care and include solid tumor therapeutics, agents for real-time image-guided surgery, and therapeutic cancer vaccines.
- Apr 2025Series B$12.7M
- Mar 2025Grant (prize money)$1.8M
- Oct 2021Series B$68.4M
- Jun 2021Series B—
#11
Series C · Houston, Texas · founded 2019$27.4Mraised▾
Developer of immunotherapeutics for the treatment of cancer. It offers a pipeline of drug candidates based on T regulatory cells and a small molecule inhibitor that blocks the transcriptional activity in cancer cells. It provides drugs for breast, lung, prostate, colorectal, and pancreatic cancer treatment.
- Apr 2025Series C$62.6M
- Jan 2025Series B$20.8M
- Feb 2024Series B$14.5M
- Aug 2022Series B$12.9M
#12
Public · Austin, Texas · founded 1996 · 20 employees$23.6Mraised▾
Provider of therapeutics for multiple cancer treatments. It offers its propriety liposomal nanotechnology platform to help in the reformulation of cancer medicines and target drug delivery. Its leading candidate is DocePLUS which targets Small Cell Lung and others cancer Breast Ovarian Multiple Myeloma Kaposi's Sarcoma.
- Feb 2025Post IPO$3.7M
- Feb 2025Grant (prize money)$2M
- May 2024Post IPO—
- Aug 2022Grant (prize money)$17.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Oncology in Texas is moving
A read on the academic research around Oncology in Texas — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 955 papers.
MD Anderson and UT Southwestern lead Texas oncology research, dominantly advancing CAR-T cell therapy and cancer immunotherapy biomarkers, with an optimistic stance reflecting breakthroughs outpacing concerns.
- The University of Texas MD Anderson Cancer Center559
- The University of Texas Southwestern Medical Center140
- The University of Texas Health Science Center at Houston73
- Texas A&M University61
- The University of Texas at Austin40
- Tumor microenvironment12→136
- Immune system8→99
- Cancer research13→102
- Immunotherapy3→71
- Cancer immunotherapy1→46
- Tumor microenvironment21→226
- Immune system15→173
- Immunotherapy10→148
- Cancer research26→153
- Cancer4→92
- Immunotherapy1→33
- Cancer4→31
- Tumor microenvironment6→32
- Cancer immunotherapy1→14
- Cancer research7→17
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.